Skip to main content

2016 First Annual Oncology Guide to New FDA Approvals

Drug Profiles/Updates, FDA Updates

Keytruda (Pembrolizumab): First PD-1 Inhibitor Approved for the Treatment of Patients with Metastatic Non–Small-Cell Lung Cancer Expressing PD-L1

Lisa A. Raedler, PhD, RPh, Medical Writer

FDA Updates

A Pipeline Preview of 2016 FDA Approvals in Hematology/Oncology

Ryan Beechinor, PharmD, BCPS, CPP, John M. Valgus, PharmD, MHA, BCOP

Drug Profiles/Updates, FDA Updates

Zarxio (Filgrastim-sndz): First Biosimilar Approved in the United States

Lisa A. Raedler, PhD, RPh, Medical Writer

Drug Profiles/Updates, FDA Updates

Varubi (Rolapitant) Approved for the Prevention of Delayed-Onset Chemotherapy-Induced Nausea and Vomiting

Lisa A. Raedler, PhD, RPh, Medical Writer

Drug Profiles/Updates, FDA Updates

Revlimid (Lenalidomide) Now FDA Approved as First-Line Therapy for Patients with Multiple Myeloma

Lisa A. Raedler, PhD, RPh, Medical Writer

Drug Profiles/Updates, FDA Updates

Portrazza (Necitumumab), an IgG1 Monoclonal Antibody, FDA Approved for Advanced Squamous Non–Small-Cell Lung Cancer

Loretta Fala, Medical Writer

Drug Profiles/Updates, FDA Updates

Pomalyst (Pomalidomide) Received a New Indication for Patients with Relapsed and/or Refractory Multiple Myeloma

Lisa A. Raedler, PhD, RPh, Medical Writer

Drug Profiles/Updates, FDA Updates

Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Lisa A. Raedler, PhD, RPh, Medical Writer

Drug Profiles/Updates, FDA Updates

Lonsurf (Trifluridine plus Tipiracil): A New Oral Treatment Approved for Patients with Metastatic Colorectal Cancer

Lisa A. Raedler, PhD, RPh, Medical Writer

FDA Updates

Welcome to the First Annual Oncology Pharmacy Guide to New FDA Approvals

1
2

Page 1 of 2
Results 1 - 10 of 18